Teresa S. Latham, DrPH

Member, Division of Hematology
Director, Clinical Research, Cancer and Blood Diseases Institute
Assistant Professor, UC Department of Pediatrics

About

DrPH: Indiana University, Fairbanks School of Public Health,

MA: Marymount University,

Services and Specialties

Interests

Sickle cell anemia; global health; public health; healthcare infrastructure and capacity building in resource-limited settings

Research Areas

Publications

Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations. Power-Hays, A; Mcelhinney, KE; Williams, TN; Mochamah, G; Olupot-Olupot, P; Paasi, G; Reid, ME; Rankine-Mullings, AE; Opoka, RO; John, CC; Stuber, SE; Latham, TS; Vinks, AA; Ware, RE. Blood advances. 2026; 10(2):418-427.

Development of disease-specific growth curves from Kenyan children with sickle cell anemia. Tomlinson, GA; Backeljauw, P; Mochamah, G; Smart, LR; Latham, TS; Ware, RE; Williams, TN. Blood Glob Hematol. 2025; 1(3):100031.

Benefits of hydroxyurea in hemoglobin SC: Results of the open-label phase of the prospective identification of variables as outcomes for treatment (PIVOT) trial. Smart, L; Dei-Adomakoh, Y; Lane, A; Ekpale, P; Koni, L; Corquaye, O; Mensah, E; Stuber, S; Latham, T; Segbefia, C; Ware, R. Blood. 2025; 146(Supplement 1):409.

Full assessment of clinical transfusion support (FACTS): A prospective Study to determine the burden of sickle cell anemia on pediatric blood transfusion use in a malaria-endemic region in Africa. Power-Hays, A; Namazzi, R; Mcelhinney, K; Kincaid, A; Kato, C; Aliwuya, S; Opoka, R; Conroy, A; John, C; Hume, HA; Stuber, S; Latham, T; Ware, R. Blood. 2025; 146(Supplement 1):300-300.

Health status of Ugandan children born with sickle cell anemia and congenital HIV identified through newborn screening. Latham, T; Kiyaga, C; Hernandez, A; Nakafeero, M; Kadde, N; Khainza, P; Stuber, S; Ndeezi, G; Aceng, J; Ware, R. Blood. 2025; 146(Supplement 1):2668.

Measles vaccine-induced sero-protection among children with sickle cell anemia. Power-Hays, A; Kincaid, A; Mcelhinney, K; Latham, T; Quinn, C; Frenck, R; Ware, R. Blood. 2025; 146(Supplement 1):1168.

Pharmacokinetic (PK)-guided vs weight-based dosing of hydroxyurea for tanzanian children with sickle cell anemia. Smart, L; Ambrose, E; Charles, M; Mcelhinney, K; Lane, A; Stuber, S; Latham, T; Ware, R. Blood. 2025; 146(Supplement 1):2959-2959.

Safety and efficacy of ten years of hydroxyurea treatment for young children with sickle cell anemia in Uganda. Ware, R; Opoka, R; Latham, T; Kasirye, P; Kasembo, P; Hume, HA; Birungi, I; Kadde, N; Wambaka, B; Nakafeero, M; Lane, A; John, C. Blood. 2025; 146(Supplement 1):412.

Splenomegaly patterns and clinical impact in African children with sickle cell anemia on hydroxyurea treatment. Tshilolo, L; Tomlinson, G; Smart, L; Latham, T; Olupot-Olupot, P; Santos, B; Aygun, B; Stuber, S; Lane, A; Williams, T; Ware, R. Blood. 2025; 146(Supplement 1):2971-2971.

Stroke prevention in Hispanic children with sickle cell anemia: the SACRED trial. Nieves, RM; Latham, T; Marte, N; Berges, M; Sánchez, LM; Urcuyo, G; Florencio, C; Gonzalez, C; Del Villar, P; Chen, S; Schultz, WH; Lane, AC; Mena, R; Ware, RE. Blood advances. 2025; 9(8):1791-1800.